Rosetta Genomics Shares Jump as Co. Announces Credentialing Deal with Three Rivers Provider Network

RosettaGenomics Ltd. (NASDAQ: ROSG), a leading developer and provider ofmicroRNA-based molecular diagnostics, announces that the Company has executeda credentialing agreement with Three Rivers Provider Network, Inc. (TRPN) ofChula Vista, Calif., for the Rosetta Cancer Origin Test.  TRPN is one of thelargest supplemental Preferred Provider Organizations (PPO) in the U.S.,providing healthcare benefits to more than 10 million members nationwide."This is the second credentialing agreement executed between Rosetta and aU.S. PPO.  Together with Medicare reimbursement, the total number of coveredlives and for which the Rosetta Cancer Origin Test could be adjudicated as'in-network' now exceeds 61 million, which means that one-in-five Americansare covered for the Rosetta Cancer Origin Test," said Kenneth A. BerlinPresident and Chief Executive Officer of Rosetta Genomics.  "We continue topursue additional agreements with other PPOs as they provide faster paymentwhile maintaining acceptable levels of reimbursement, and also reduce costsincurred through appealing denials.  This has become increasingly important toour company as we continue to see a growing number of samples being processedand billed by our CLIA lab.""This agreement comes at a good time for Rosetta as it follows on our strongpresence at ASCO 2013, where we significantly enhanced the awareness of theCancer Origin Test among an audience of the world's leading oncologists andresearchers.  In addition, positive trends in billable and processed samplesfor the Cancer Origin Test have led us to begin expansion of our salesterritories from 5 to 12.  The credentialing agreement with TRPN furtherenhances our ability to gain traction in the market and to further increaseaccess of this test to patients with a CUP diagnosis."With more than 200,000 patients per year presenting with Cancer of Unknown orUncertain Primary (CUP) or who would otherwise benefit from this test, thisexpanding coverage reflects the importance of determining the tumor origin inhard-to-diagnose metastatic cancers and CUP.  This is particularly importantas new, molecularly-targeted cancer treatments are developed.  We believe theRosetta Cancer Origin Test^™ can  help physicians to accurately diagnose tumororigin in order to optimize treatment. The availability and accuracy of ourCancer Origin Test underscores why the uncertainty of CUP is no longeracceptable," Mr. Berlin added. A PPO is a managed care organization of medical doctors, hospitals and otherhealth care providers that has covenanted with an insurer or a third-partyadministrator to provide health care at reduced rates to the insurer's oradministrator's clients. Credentialing is a process whereby providerorganizations such as physicians, care facilities and ancillary providers(including testing service providers such as Rosetta Genomics') contractdirectly with the PPO.